Identification of an interferon-γ-inducible carcinoembryonic antigen (CEA) CD8+ T-cell epitope, which mediates tumor killing in CEA transgenic mice

Cancer Research

Volumn 62, Issue 17, 2002, Pages 5058-5064

  Schmitz, John ^a   Reali, Eva ^a   Hodge, James W ^a   Patel, Arti ^a   Davis, Garland ^a   Schlom, Jeffrey ^a   Greiner, John W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD8 ANTIGEN; EPITOPE; FAS ANTIBODY; FAS LIGAND; GAMMA INTERFERON; H2 ANTIGEN; IMMUNOLOGICAL ADJUVANT; PERFORIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CYTOLYSIS; CYTOTOXICITY; FEMALE; GENE EXPRESSION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ADENOCARCINOMA; ANIMALS; CARCINOEMBRYONIC ANTIGEN; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036732043     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. T cell tolerance and activation to a transgene-encoded tumor antigen
2. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen
3. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques
4. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
5. Carcinoembryonic antigen, a human tumor marker, functions as an intracellular adhesion molecule
6. Escherichia coli of human origin binds to carcinoembryonic antigen (CEA) and non-specific cross-reacting antigen (NCA)
7. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis
8. Human carcinoembryonic antigen functions as a general inhibitor of anoikis
9. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG
10. Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer
11. Pharmacological administration of granulocyta/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoem-bryonic antigen
12. Phase I study in cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
13. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas
14. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine
15. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern
16. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy
17. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus
18. Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen
19. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant
20. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice
21. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T-cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice
22. Transduction and expression of the human carcinoembryonic antigen (CEA) gene in a murine colon carcinoma cell line
23. Definition of monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinoma versus normal adult tissues
24. gp100/pme1 12 is a murine tumor rejection antigen: Induction of self reactive, tumoricidal T cells using high affinity altered peptide ligand
25. Non-parametric estimation from incomplete observation
26. Evaluation of survival data and two new rank order statistics arising in its consideration
27. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
28. Fas and perforin pathways as major mechanisms of T-cell-mediated cytotoxicity
29. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor capacity
30. Concanamycin A a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity
31. Negative selection of lymphocytes
32. MHC ligands and peptide motifs: First listing
33. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
34. Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity
35. Modulation of carcinoembryonic antigen mRNA levels in human colon carcinoma cells by recombinant γ interferon
36. Cytotoxic T cells specifically induce Fas on targets, thereby facilitating exocytosis-independent induction of apoptosis
37. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production
38. The pathophysiology of tumor necrosis factors
39. Cell death induced by the Fas/Fas ligand pathway and its role in pathology
40. The specificity of proteasomes impact on MHC class I processing and presentation of antigens
41. T-cell tolerance
42. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects